St. John Properties, Inc. has signed Eisai Inc., the United States pharmaceutical subsidiary of Tokyo-based Eisai Co, Ltd., to a 40,000-square-foot full-building lease within 11675 Crossroads Circle. The flex/R&D building was built on a speculative basis, and is located within Greenleigh at Crossroads, a 550-acre mixed-use community in the White Marsh area of Baltimore County. The company plans to relocate approximately 55 employees from its existing location in Baltimore City in 2019, after construction at the site is completed. Matt Lenihan of St. John Properties represented the landlord in this transaction.
Eisai Inc. is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities.
The Greenleigh at Crossroads facility will be used to manufacture and distribute Gliadel®, a product used to treat brain cancer.